CEPHIA Public Use Data

Public use dataset from the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)'s evaluations of HIV recency assays. Samples tested by CEPHIA were obtained from numerous collaborators. See the acknowledgements below: Funding CEPHIA was supported by grants from the Bill and Melinda Gates Foundation (OPP1017716 to G.M., OPP1062806 to C.D.P. and OPP1115799). Additional support for analysis was provided by a grant from the US National Institutes of Health (R34 MH096606 to C.D.P.) and by the South African Department of Science and Technology and the National Research Foundation. Specimen and data collection were funded in part by grants from the NIH (P01 AI071713, R01 HD074511, P30 AI027763, R24 AI067039, U01 AI043638, P01 AI074621 and R24 AI106039); the HIV Prevention Trials Network (HPTN) sponsored by the NIAID, National Institutes of Child Health and Human Development (NICH/HD), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (UM1 AI068613 and R01 AI095068); the California HIV-1 Research Program (RN07-SD-702); Brazilian Program for STD and AIDS, Ministry of Health (914/BRA/3014-UNESCO); and the São Paulo City Health Department (2004-0.168.922– 7). Selected samples from International AIDS Vaccine Initiative (IAVI)-supported cohorts were funded by IAVI with the generous support of USAID and other donors; a full list of IAVI donors is available at www.iavi.org. Acknowledgements The Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) comprises: Alex Welte, Joseph Sempa, formerly: David Matten, Hilmarie ́ Brand, Trust Chiba- wara (South African Centre for Epidemiological Modelling and Analysis, Stellenbosch Univer- sity); Gary Murphy, Jake Hall, formerly: Elaine Mckinney (Public Health England); Michael P. Busch, Eduard Grebe, Shelley Facente, Dylan Hampton, Sheila Keating, formerly: Mila Lebe- deva (Vitalant Research Institute, formerly Blood Systems Research Institute); Christopher D. Pilcher, Kara Marson (University of California San Francisco); Reshma Kassanjee (University of Cape Town); Oliver Laeyendecker, Thomas Quinn, David Burns (National Institutes of Health); Susan Little (University of California San Diego); Anita Sands (World Health Organi- zation); Tim Hallett (Imperial College London); Sherry Michele Owen, Bharat Parekh, Connie Sexton (Centers for Disease Control and Prevention); Matthew Price, Anatoli Kamali (Interna- tional AIDS Vaccine Initiative); Lisa Loeb (The Options Study—University of California San Francisco); Jeffrey Martin, Steven G Deeks, Rebecca Hoh (The SCOPE Study—University of California San Francisco); Zelinda Bartolomei, Natalia Cerqueira (The AMPLIAR Cohort— University of São Paulo); Breno Santos, Kellin Zabtoski, Rita de Cassia Alves Lira (The AMPLIAR Cohort—Grupo Hospital Conceic ̧ão); Rosa Dea Sperhacke, Leonardo R Motta, Machline Paganella (The AMPLIAR Cohort—Universidade Caxias Do Sul); Esper Kallas, Helena Tomiyama, Claudia Tomiyama, Priscilla Costa, Maria A Nunes, Gisele Reis, Mariana M Sauer, Natalia Cerqueira, Zelinda Nakagawa, Lilian Ferrari, Ana P Amaral, Karine Milani (The São Paulo Cohort—University of São Paulo, Brazil); Salim S Abdool Karim, Quarraisha Abdool Karim, Thumbi Ndungu, Nelisile Majola, Natasha Samsunder (CAPRISA, University of Kwazulu-Natal); Denise Naniche (The GAMA Study—Barcelona Centre for International Health Research); Ina ́cio Mandomando, Eusebio V Macete (The GAMA Study—Fundacao Manhica); Jorge Sanchez, Javier Lama (SABES Cohort—Asociacio ́n Civil Impacta Salud y Educacio ́n (IMPACTA)); Ann Duerr (The Fred Hutchinson Cancer Research Center); Maria R Capobianchi (National Institute for Infectious Diseases “L. Spallanzani”, Rome); Barbara Suligoi (Istituto Superiore di Sanità, Rome); Susan Stramer (American Red Cross); Phillip Wil- liamson (Creative Testing Solutions / Vitalant Research Institute); Marion Vermeulen (South African National Blood Service); and Ester Sabino (Hemocentro do São Paolo).